US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
biotech · Respiratory Distress Syndrome · Cardiogenic Shock · WINT
WINDTREE THERAPEUTICS INC
WINDTREE THERAPEUTICS INC /DE/
WINDTREE THERAPEUTICS INC drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
2600 Kelly Rd., Suite 100, Warrington, PA 18976, US HQ
1992 Founded
17 Employees
Public company Type
WINT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 2600 Kelly Rd., Suite 100, Warrington, PA 18976, US
- Founded
- 1992
- Employees
- 17
- Programs
- 15
- Drugs
- 9
- Patents
- 4
WINDTREE THERAPEUTICS INC pipeline
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
WINDTREE THERAPEUTICS INC drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in WINDTREE THERAPEUTICS INC's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
Development asset linked to WINDTREE THERAPEUTICS INC in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Surfactant agent.
- Mechanism
- Surfactant agent
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
pioglitazone
Alimentary tract and metabolism (A10)Alimentary tract and metabolism (A10) compound in WINDTREE THERAPEUTICS INC's portfolio. Mechanism: Peroxisome proliferator-activated receptor gamma agonist.
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor gamma.
- Target
- Peroxisome proliferator-activated receptor gamma
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
-
Development asset linked to WINDTREE THERAPEUTICS INC in public FDA and regional records.